345 related articles for article (PubMed ID: 18182259)
1. Plasmid DNA loaded chitosan nanoparticles for nasal mucosal immunization against hepatitis B.
Khatri K; Goyal AK; Gupta PN; Mishra N; Vyas SP
Int J Pharm; 2008 Apr; 354(1-2):235-41. PubMed ID: 18182259
[TBL] [Abstract][Full Text] [Related]
2. Strong systemic and mucosal immune responses to surface-modified PLGA microspheres containing recombinant hepatitis B antigen administered intranasally.
Jaganathan KS; Vyas SP
Vaccine; 2006 May; 24(19):4201-11. PubMed ID: 16446012
[TBL] [Abstract][Full Text] [Related]
3. Mannosylated niosomes as adjuvant-carrier system for oral genetic immunization against hepatitis B.
Jain S; Singh P; Mishra V; Vyas SP
Immunol Lett; 2005 Oct; 101(1):41-9. PubMed ID: 15869802
[TBL] [Abstract][Full Text] [Related]
4. Cationic transfersomes based topical genetic vaccine against hepatitis B.
Mahor S; Rawat A; Dubey PK; Gupta PN; Khatri K; Goyal AK; Vyas SP
Int J Pharm; 2007 Aug; 340(1-2):13-9. PubMed ID: 17446015
[TBL] [Abstract][Full Text] [Related]
5. Immune response by nasal delivery of hepatitis B surface antigen and codelivery of a CpG ODN in alginate coated chitosan nanoparticles.
Borges O; Cordeiro-da-Silva A; Tavares J; Santarém N; de Sousa A; Borchard G; Junginger HE
Eur J Pharm Biopharm; 2008 Jun; 69(2):405-16. PubMed ID: 18364251
[TBL] [Abstract][Full Text] [Related]
6. Surface modified liposomes for nasal delivery of DNA vaccine.
Khatri K; Goyal AK; Gupta PN; Mishra N; Mehta A; Vyas SP
Vaccine; 2008 Apr; 26(18):2225-33. PubMed ID: 18396362
[TBL] [Abstract][Full Text] [Related]
7. Development and characterization of chitosan coated poly-(ɛ-caprolactone) nanoparticulate system for effective immunization against influenza.
Gupta NK; Tomar P; Sharma V; Dixit VK
Vaccine; 2011 Nov; 29(48):9026-37. PubMed ID: 21939718
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of ISCOM vaccines for mucosal immunization against hepatitis B.
Pandey RS; Dixit VK
J Drug Target; 2010 May; 18(4):282-91. PubMed ID: 19958131
[TBL] [Abstract][Full Text] [Related]
9. Chitosan-based nanoparticles for improving immunization against hepatitis B infection.
Prego C; Paolicelli P; Díaz B; Vicente S; Sánchez A; González-Fernández A; Alonso MJ
Vaccine; 2010 Mar; 28(14):2607-14. PubMed ID: 20096389
[TBL] [Abstract][Full Text] [Related]
10. Poly(propyleneimine) dendrimer and dendrosome mediated genetic immunization against hepatitis B.
Dutta T; Garg M; Jain NK
Vaccine; 2008 Jun; 26(27-28):3389-94. PubMed ID: 18511160
[TBL] [Abstract][Full Text] [Related]
11. Engineering enhancement of the immune response to HBV DNA vaccine in mice by the use of LIGHT gene adjuvant.
Zhang Y; Jiang W; Fan Y; Wen J; Hao W; Qian M
J Virol Methods; 2008 Nov; 153(2):142-8. PubMed ID: 18722475
[TBL] [Abstract][Full Text] [Related]
12. Novel chitosan derivative nanoparticles enhance the immunogenicity of a DNA vaccine encoding hepatitis B virus core antigen in mice.
Jiang L; Qian F; He X; Wang F; Ren D; He Y; Li K; Sun S; Yin C
J Gene Med; 2007 Apr; 9(4):253-64. PubMed ID: 17397104
[TBL] [Abstract][Full Text] [Related]
13. Mono-N-carboxymethyl chitosan (MCC) and N-trimethyl chitosan (TMC) nanoparticles for non-invasive vaccine delivery.
Sayin B; Somavarapu S; Li XW; Thanou M; Sesardic D; Alpar HO; Senel S
Int J Pharm; 2008 Nov; 363(1-2):139-48. PubMed ID: 18662762
[TBL] [Abstract][Full Text] [Related]
14. Intranasal immunization with chitosan/pCETP nanoparticles inhibits atherosclerosis in a rabbit model of atherosclerosis.
Yuan X; Yang X; Cai D; Mao D; Wu J; Zong L; Liu J
Vaccine; 2008 Jul; 26(29-30):3727-34. PubMed ID: 18524427
[TBL] [Abstract][Full Text] [Related]
15. Intranasal administration of plasmid DNA-coated nanoparticles results in enhanced immune responses.
Cui Z; Mumper RJ
J Pharm Pharmacol; 2002 Sep; 54(9):1195-203. PubMed ID: 12356273
[TBL] [Abstract][Full Text] [Related]
16. Nasal vaccination with N-trimethyl chitosan and PLGA based nanoparticles: nanoparticle characteristics determine quality and strength of the antibody response in mice against the encapsulated antigen.
Slütter B; Bal S; Keijzer C; Mallants R; Hagenaars N; Que I; Kaijzel E; van Eden W; Augustijns P; Löwik C; Bouwstra J; Broere F; Jiskoot W
Vaccine; 2010 Aug; 28(38):6282-91. PubMed ID: 20638455
[TBL] [Abstract][Full Text] [Related]
17. Alginate coated chitosan nanoparticles are an effective subcutaneous adjuvant for hepatitis B surface antigen.
Borges O; Silva M; de Sousa A; Borchard G; Junginger HE; Cordeiro-da-Silva A
Int Immunopharmacol; 2008 Dec; 8(13-14):1773-80. PubMed ID: 18801462
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis B surface antigen nanoparticles coated with chitosan and trimethyl chitosan: Impact of formulation on physicochemical and immunological characteristics.
Tafaghodi M; Saluja V; Kersten GF; Kraan H; Slütter B; Amorij JP; Jiskoot W
Vaccine; 2012 Aug; 30(36):5341-8. PubMed ID: 22749834
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the immune response following a short oral vaccination schedule with hepatitis B antigen encapsulated into alginate-coated chitosan nanoparticles.
Borges O; Tavares J; de Sousa A; Borchard G; Junginger HE; Cordeiro-da-Silva A
Eur J Pharm Sci; 2007 Dec; 32(4-5):278-90. PubMed ID: 17884394
[TBL] [Abstract][Full Text] [Related]
20. Pharmaceutical and immunological evaluation of mucoadhesive nanoparticles based delivery system(s) administered intranasally.
Mangal S; Pawar D; Garg NK; Jain AK; Vyas SP; Rao DS; Jaganathan KS
Vaccine; 2011 Jul; 29(31):4953-62. PubMed ID: 21575664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
